Inactive

DESCRIPTION The U.S. Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Cancer Signaling Networks S... DESCRIPTION The U.S. Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Cancer Signaling Networks Section of the Thoracic and GI Oncology Branch (TGIB) wants to lease of Thermo ScientificTM Orbitrap Exploris 480 Mass Spectrometer along with ULTIMATE 3000 Binary RS nano-LC System and FAIMS (field asymmetric ion mobility spectrometry) Pro interface. This is a combined synopsis/solicitation for commercial items, prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice, and shall be processed in accordance with FAR Part 13 – Simplified Acquisition Procedures. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation, 75N91020Q00013, is issued as a request for quote (RFQ) and includes all applicable provisions and clauses in effect through FAR Federal Acquisition Circular (FAC) 2020-04 (01-15-2020) simplified acquisition procedures for commercial items. The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type purchase order. BRAND NAME OR EQUAL This requirement is for the procurement of the brand name or equivalent instruments described in section 4.0. The Federal Acquisition Regulation (FAR) provision FAR 52.211-6, Brand Name or Equal (AUG 1999) is applicable to this requirement. BACKGROUND The Orbitrap Exploris 480 Mass Spectrometer and the accompanying ULTIMATE 3000 Binary RS nano-LC System and FAIMS Pro interface will be used for the proteomics work in the National Cancer Institute (NCI), Center for Cancer Research (CCR) Cancer Signaling Networks Section of the Thoracic and GI Oncology Branch (TGIB). The NCI is using quantitative mass spectrometry-based approach to identify direct or indirect targets of mutant EGFR (epidermal growth factor receptor) signaling in lung cancer and the mechanisms of TKI (Tyrosine kinase inhibitor) resistance, biomarkers of TKI response, and potential targets for treatment. See the attached for RFQ details